Carboplatin (Cb), weekly nanoparticle, albumin-bound paclitaxel (wAb), and bevacizumab (Av) neoadjuvant chemotherapy (NAC) in HER2-negative breast cancer (BrCA): A BrUOG study.
N. Sinclair
No relevant relationships to disclose
M. M. Abu-Khalaf
No relevant relationships to disclose
B. J. Sakr
No relevant relationships to disclose
T. Rizack
No relevant relationships to disclose
D. R. Lannin
No relevant relationships to disclose
J. S. Gass
No relevant relationships to disclose
R. Strenger
No relevant relationships to disclose
V. Bossuyt
No relevant relationships to disclose
M. A. Fenton
No relevant relationships to disclose
L. Harris
No relevant relationships to disclose
W. M. Sikov
Research Funding - Abraxis BioScience